Home > Boards > US Listed > Biotechs >

GT Biopharma Inc. (GTBP)

Add GTBP Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 8/4/2020 9:10:04 PM - Followers: 170 - Board type: Free - Posts Today: 0


The Scourge of Cancer

Cancer is the second leading cause of death globally, and responsible for 8.8 million deaths annually.  The economic impact of cancer is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion.  Immuno Oncology sits on the leading edge of cancer treatment and research.  In terms of effectiveness it promises to drastically outpace all previous forms of conventional cancer therapy.  Some estimate the Immuno Oncology market at $US 40 Billon and growing.

What is Immuno Oncology?

Immuno Oncology is treatment that recruits and supercharges a person's own immune system components to fight cancer. This can take various forms: the immune system can be stimulated to work harder or smarter in attacking cancer cells, immune system components can be supplied such as man-made immune proteins that attack cancer cells in a targeted way, immune system cells can be "programmed" to only attack very specific cancer cells or even to deliver a "payload" of compounds poisonous to cancer directly and only to the malignant cells. 


Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy
Conventional chemotherapy poisons the patient's body with the aim of getting the cancer too. Its like spraying a powerful herbicide on your rose garden to get rid of the dandelions. Yes, the weeds will die but the roses will suffer too.

With Immuno Oncology, the cure is not worse than the disease. Many of the harsh and debilitating side effects of chemotherapy are avoided because the agents that kill the cancer are components of the human immune system itself, rather than poison, and the therapy can be precisely targeted to only attack the cancerous cells.  It is truly the next evolutionary leap in cancer treatment.   

GT Biopharma Portfolio

GTBP Therapy Pipeline Highlights

OXS-1550: Treating Lymphoma and Leukemia
When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.  OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.

The initial phase 1 study enrolled 25 patients (who) received at least a single course of therapy. The treatment at the higher doses produced objective tumor responses with one patient in continuous partial remission and the second in complete remission. Data from ongoing phase 2 expected in 2H ‘18.

OXS-3550: Treating Leukemia
The OXS-3550 IND will focus on AML, the most common form of adult leukemia with 21,000 new cases expected in 2017 alone (American Cancer Society). These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline, a therapy that has not changed in over 40 years.

OXS-1615 AND OXS-C3550: Treating Solid Tumors
This TetraKE is designed to kill not only the heterogeneous population of cancer cells found in solid tumors but also kill the cancer stem cells that are typically responsible for recurrences.

Other Offerings: Central Nervous System Therapies

GTP-011: Motion Sickness Treatment

GTP-011 is a 72-hour patch for which a patent application has been filed by GTP for the prevention of motion sickness, a well-known syndrome that typically involves nausea and vomiting in otherwise healthy people and that occurs upon exposure to certain types of motion.

PainBrake: Treating Neuropathic Pain 
PainBrake® is a new patented formulation of carbamazepine (Tegretol®) that enables accurate dose fractionation for the treatment of neuropathic pain.  An NIH-supported study estimated that almost 16 million Americans suffer from chronic neuropathic pain. Current drugs provide a useful degree of pain relief in only about half the patients. 

GTP-004: Treating Myasthenia Gravis
GTP-004 is a fixed-dose combination tablet for the treatment of myasthenia gravis. Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The prevalence of the disease in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. 


GT Biopharma Executive Team: A Who's Who Of The Biotech Sector

"Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets.  Some of the biotech sector’s most affluent and influential individuals are making a move... to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders."


Company Website

GTBP Investor's Overview


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 08/18/2020 05:01:39 PM
GTBP News: Quarterly Report (10-q) 08/14/2020 05:03:50 PM
GTBP News: Notice of Effectiveness (effect) 07/29/2020 06:06:56 AM
GTBP News: Amended Small Company Offering and Sale of Securities Without Registration (d/a) 07/23/2020 05:01:25 PM
GTBP News: Securities Registration Statement (s-1) 07/14/2020 05:02:25 PM
#18517   IS ANYBODY ELSE WATCHING THE NEWS moneemkr 08/04/20 09:10:03 PM
#18516   rallied big on that last dip. narrow spread TX MA 05/20/20 08:42:09 PM
#18515   .065 spread between bid & offer. .135-.20. Jacque_Strap 04/14/20 09:38:53 AM
#18514   Damn! The offering is sooo thin. Jacque_Strap 04/06/20 09:36:02 AM
#18513   I got the remainder filled yesterday.... growacet 03/17/20 11:34:56 AM
#18512   I'm in, just a partial fill so far.... growacet 03/16/20 10:39:30 AM
#18511   Guess that was all hype PR. If Gumby525 03/12/20 10:12:42 AM
#18510   What makes you think there is dilution? I eageleye 03/11/20 12:38:04 PM
#18509   Dilution and conversions will kill ya every time, Involuntary-Recluse 03/11/20 12:14:05 PM
#18508   GTBP is no HLTY folks :-) Involuntary-Recluse 03/11/20 11:48:37 AM
#18507   Looks like a large buy order and double eageleye 03/11/20 11:38:03 AM
#18506   Decent volume, not over the top, but decent. eageleye 03/11/20 10:56:08 AM
#18505   GTBP $$$ LOADING MORE SHARES HERE, ITS DIRT halbroke1 03/11/20 10:17:55 AM
#18504   creeping up undetected +11.7% 81vette 03/11/20 09:46:34 AM
#18503   $650,499 Was actually the days total actual $$$ DERBYBLOOD 03/11/20 06:10:58 AM
#18502   Cut your losses here folks, way too much Involuntary-Recluse 03/10/20 03:53:23 PM
#18501   I see everyone took their profits today. Gumby525 03/10/20 03:25:36 PM
#18500   could take,day or3 for whales to dd,and ppl 81vette 03/10/20 01:40:55 PM
#18499   I've reloaded at .2199! vinc 03/10/20 01:22:20 PM
#18498   Hopefully true. Volume is pretty weak. Gumby525 03/10/20 01:13:52 PM
#18497   Excellent article from today: https://alphastocknews.com/gt-biopharma-gtbp-stock-may-be-the-next-big vinc 03/10/20 01:08:11 PM
#18496   Beautiful slap of 43K at .24! Seems that vinc 03/10/20 01:00:17 PM
#18495   $375,000 traded,this is big 81vette 03/10/20 01:00:00 PM
#18494   It would be good for my red stocks list... vinc 03/10/20 12:53:08 PM
#18493   if news true,mkt will find,easy $2.00pps 81vette 03/10/20 12:51:02 PM
#18492   thru .27 is a 10 month high 81vette 03/10/20 12:40:22 PM
#18491   .30 will be easily reach before the close! vinc 03/10/20 12:37:53 PM
#18490   nice,force strong,blows thru pennies,bid building .24 81vette 03/10/20 12:36:41 PM
#18489   In at .235! vinc 03/10/20 12:32:07 PM
#18488   current ss info click here>Market Cap 81vette 03/10/20 11:02:45 AM
#18487   Just another broke OTC ticker in GTBP jumping elkonig 03/10/20 10:58:09 AM
#18486   collaboration company> https://finance.yahoo.com/quote/002399.SZ/ 81vette 03/10/20 10:20:21 AM
#18485   GTBP $$$ BIG NEWS OUT !!! THE MARKET halbroke1 03/10/20 10:09:14 AM
#18484   https://www.otcmarkets.com/stock/GTBP/news/GT-Biopharma-and-Cytovance-Biologics- 81vette 03/10/20 09:57:28 AM
#18483   conversions/preferred shares selling,huge run,if/when gone 81vette 03/10/20 09:56:06 AM
#18482   Please, elaborate....thanks idccwin 03/10/20 09:46:55 AM
#18481   coronavirus deal,$24.00pps company,could run big 81vette 03/10/20 09:38:53 AM
#18480   Hey Stranger Two3 02/20/20 12:26:08 PM
#18479   Seems like the last promo campaign didn’t do CashBowski 12/09/19 11:21:46 AM
#18478   U2 buddy, compare more notes soon! doogdilinger 11/18/19 11:38:08 AM
#18477   Agreed! Ty, have a great week! Two3 11/18/19 10:48:40 AM
#18476   Same as our last convo, mgmt. just needs doogdilinger 11/18/19 10:34:13 AM
#18475   Thoughts? Two3 11/18/19 10:13:18 AM
#18474   I hear your time is just about up ?????????????????? IB_ 11/15/19 11:00:36 PM
#18473   Me too buddy! Hopefully mgmt. recognizes the need doogdilinger 11/08/19 04:54:30 PM
#18472   Any thoughts? Company needs to keep that news Two3 11/07/19 08:59:11 PM
#18471   Exactly buddy, we'll see how this plays out doogdilinger 11/05/19 01:04:30 PM
#18470   Yes Sir! Balls in Mgmt hands now, hoping Two3 11/04/19 11:12:37 AM
#18469   GM Two3 buddy, early profit takers churned out doogdilinger 11/04/19 10:33:40 AM
#18468   Morning $$$GTBP$$$ Two3 11/04/19 09:35:09 AM
Consent Preferences